210 related articles for article (PubMed ID: 15200346)
1. Fluvastatin: clinical and safety profile.
Corsini A; Jacobson TA; Ballantyne CM
Drugs; 2004; 64(12):1305-23. PubMed ID: 15200346
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin: a review of its use in lipid disorders.
Langtry HD; Markham A
Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694
[TBL] [Abstract][Full Text] [Related]
3. The use of fluvastatin in cardiovascular risk management.
McDonald KJ; Jardine AG
Expert Opin Pharmacother; 2008 Jun; 9(8):1407-14. PubMed ID: 18473714
[TBL] [Abstract][Full Text] [Related]
4. A review of the lipid-related effects of fluvastatin.
Liberopoulos EN; Daskalopoulou SS; Mikhailidis DP; Wierzbicki AS; Elisaf MS
Curr Med Res Opin; 2005 Feb; 21(2):231-44. PubMed ID: 15801994
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin: efficacy and safety in reducing cardiac events.
Chan MY; Lee CH
Expert Opin Pharmacother; 2005 Sep; 6(11):1883-95. PubMed ID: 16144508
[TBL] [Abstract][Full Text] [Related]
6. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.
Voûte MT; Winkel TA; Poldermans D
Expert Opin Drug Saf; 2010 Sep; 9(5):793-800. PubMed ID: 20557267
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age.
Bruckert E; Verpilleux MP; Dejager S; Isaacsohn J
Am J Cardiol; 2005 Oct; 96(8):1142-8. PubMed ID: 16214453
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
9. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin.
Corsini A
Int J Clin Pract; 2004 May; 58(5):494-503. PubMed ID: 15206507
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Holdaas H; Fellström B; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Solbu DO; Pedersen TR;
Lancet; 2003 Jun; 361(9374):2024-31. PubMed ID: 12814712
[TBL] [Abstract][Full Text] [Related]
11. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
Scuffham PA; Chaplin S
Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
13. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin and perioperative events in patients undergoing vascular surgery.
Schouten O; Boersma E; Hoeks SE; Benner R; van Urk H; van Sambeek MR; Verhagen HJ; Khan NA; Dunkelgrun M; Bax JJ; Poldermans D;
N Engl J Med; 2009 Sep; 361(10):980-9. PubMed ID: 19726772
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
16. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS).
Lee CH; de Feyter P; Serruys PW; Saia F; Lemos PA; Goedhart D; Soares PR; Umans VA; Ciccone M; Cortellaro M
Heart; 2004 Oct; 90(10):1156-61. PubMed ID: 15367512
[TBL] [Abstract][Full Text] [Related]
17. Statin + fibrate combination therapy--fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Wray R; Hemsley D
Int J Cardiol; 1999 Dec; 71(3):291. PubMed ID: 10636539
[No Abstract] [Full Text] [Related]
18. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
[TBL] [Abstract][Full Text] [Related]
19. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Farnier M; Bortolini M; Salko T; Freudenreich MO; Isaacsohn JL; Troendle AJ; Gonasun L
Am J Cardiol; 2003 Jan; 91(2):238-40. PubMed ID: 12521642
[No Abstract] [Full Text] [Related]
20. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
